Anavex Life Sciences Announces FDA Meeting on Pediatric Inclusion for Rett Trial

What Happened
Anavex Life Sciences Corp. (Anavex) filed an 8-K on September 9, 2026, reporting that the U.S. Food and Drug Administration has granted the company’s request for a meeting to discuss including pediatric patients in its Phase 3 clinical trial of ANAVEX®2-73 (blarcamesine) for Rett syndrome. The Phase 3 trial (ANAVEX 2-73-RS-005) is already being initiated in adult patients as part of the company’s clinical development priorities.

Key Details

• Filing date: September 9, 2026 (Form 8-K, Item 8.01 — Other Events).
• Drug: ANAVEX®2-73 (blarcamesine).
• Trial: Phase 3 Rett syndrome study ANAVEX 2-73-RS-005 — currently initiated in adults; FDA granted a meeting to discuss pediatric inclusion.
• Company focus: advancing ANAVEX 2-73 programs in early Alzheimer’s disease, Rett syndrome and Fragile X syndrome in the U.S.

Why It Matters
Regulatory meetings with the FDA are a formal step in seeking agency feedback on trial design and patient populations. Discussion of pediatric inclusion could affect the trial’s enrollment scope and future regulatory strategy for Rett syndrome. For investors, this item signals active regulatory engagement for Anavex’s lead candidate but does not report results, approvals, or changes to trial outcomes or timelines.